Exclusive: PhRMA attacks federal government's response to rebate model for 340B
The pharma industry’s DC-based lobbying group urged the federal government on Friday to get on board with alternative models for 340B drug price discounts. In a letter to the Health Resources and...
View ArticleClik here to view.
VC firm targets $35M second fund to back startups led by scientists
A small venture capital firm that backs up-and-coming scientists plans to raise a $35 million second fund, three years after coming onto the scene. SciFounders, based in the San Francisco Bay Area, is...
View ArticleTurnstone rejigs staff and exec team, eases preclinical work as cash runs low
Just over a year after going public, Turnstone Biologics is axing staff, adjusting its leadership team and changing its pipeline focus to extend its cash runway for another two years. The San Diego...
View ArticleClik here to view.
Perspective’s early data on lead-based radiopharma asset suggest lower dose...
In early-stage trials called dose escalation studies, drug developers usually want to test progressively higher doses of their therapies. Not Perspective Therapeutics. The radiopharma biotech announced...
View Article#CPHI24: European drugmakers look to reshore manufacturing but warn of price...
As European manufacturers localize their supply chains and production, they are also warning that drug prices could creep up if the European Commission doesn’t provide more regulation on drug...
View ArticleTeva to pay $450M to settle allegations of kickbacks and generic drug...
Generics giant Teva Pharmaceuticals will pay $450 million over six years to settle two allegations that the company violated the Anti-Kickback Statute and the False Claims Act, the Department of...
View ArticleClik here to view.
Sanofi lands on private equity firm CD&R as potential buyer of consumer...
Sanofi has chosen US private equity firm Clayton, Dubilier & Rice to advance acquisition talks for its consumer health unit, the pharma confirmed Friday. The company says it entered into...
View ArticleStealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare...
This week, Stealth BioTherapeutics CEO Reenie McCarthy faced a seemingly insurmountable roadblock with the company’s drug for the ultra-rare, fatal mitochondrial disease Barth syndrome. FDA reviewers...
View ArticleClik here to view.
Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine
Valneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the company’s investor day. Pfizer has sole commercial responsibility for the...
View ArticlePfizer hemophilia drug marstacimab is approved by FDA
Whew. Pfizer — after a week in which it began a showdown with an activist investor, was betrayed by and then reunited with two former top executives, and ended work on an RSV drug — finally has some...
View ArticlePfizer's situation with Starboard; Meet Endpoints' 2024 Women in Biopharma;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleEli Lilly obesity drug may go back on shortage, FDA says, in win for...
The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a trade group representing large compounding pharmacies challenged the move. A...
View ArticleClik here to view.
Transgene shares dip as therapeutic cancer vaccine disappoints in Phase 2 trial
Transgene’s therapeutic cancer vaccine candidate has failed a mid-stage test in certain HPV-driven cancers, sending its shares down around 14% Monday morning. The French biotech’s TG4001 plus Merck...
View ArticleClik here to view.
Catalent sells New Jersey plant to Belgian CDMO, plans moving HQ elsewhere
Novo Holdings is set to buy one less facility from Catalent as the manufacturer has sold a facility in New Jersey to a European CDMO. The sale also means Catalent is looking for a new corporate...
View ArticleShift Bioscience raises $16M to find genes that rewind epigenetic clock
Seven years ago, Daniel Ives believed that he was on the cusp of solving aging. He wanted to continue working on a discovery he made as a graduate student at the University of Cambridge, but couldn’t...
View ArticleClik here to view.
Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3...
Danish drugmaker Lundbeck will buy La Jolla, CA-based Longboard Pharmaceuticals for $2.6 billion in cash, the companies said Monday morning, marking the largest biopharma M&A deal since July....
View ArticleClik here to view.
Mark Pruzanski gets another shot at MASH, joining as chair of Inventiva as it...
After flashing warning signs in July with only enough money for that month, Inventiva has now secured a lifeline to keep its Phase 3 liver disease study afloat. The French biotech said Monday it got...
View ArticleNovartis ends mid-stage IPF trial, will keep testing drug in PAH
Novartis has terminated a mid-stage trial of an oral treatment candidate for idiopathic pulmonary fibrosis, the company confirmed to Endpoints News. The Swiss pharma giant axed a Phase 2 study of...
View ArticleEndpoints AI coverage: Come hear from two Nobel winners at our events
More than a year ago, Endpoints News made the decision that we needed a dedicated reporter covering the use of artificial intelligence in drug R&D. Since then, our senior correspondent Andrew Dunn...
View ArticleAkeso raises $250M; SalioGen’s layoffs
Plus, news about Nicox, Soleus and Molecular Templates: Akeso Biopharma’s $250M placement: The Hong Kong-based company, which is developing a closely watched bispecific antibody with Summit...
View Article